Alexa B. Schrock

17.2k citations

259 papers · 6.0k indexed · 1 hit paper · h-index 41

Oncology top 0.5%
Pulmonary and Respiratory Medicine top 0.5%
Cancer Research top 0.5%
Molecular Biology top 5%
Pathology and Forensic Medicine top 1%

Co-authors: Siraj M. Ali Jeffrey S. Ross Vincent A. Miller Sai‐Hong Ignatius Ou Samuel J. Klempner Philip J. Stephens Garrett M. Frampton David Fabrizio
Topics: Cancer Genomics and Diagnostics (116 papers)Lung Cancer Treatments and Mutations (98 papers)Colorectal Cancer Treatments and Studies (38 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Nature Communications Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States Italy France

In The Last Decade

Alexa B. Schrock

240 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

2019 441 citations Alexa B. Schrock, Ethan S. Sokol et al. profile →

Peers

Countries citing papers authored by Alexa B. Schrock

Since Specialization

Citations

This map shows the geographic impact of Alexa B. Schrock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexa B. Schrock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexa B. Schrock more than expected).

Fields of papers citing papers by Alexa B. Schrock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexa B. Schrock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexa B. Schrock. The network helps show where Alexa B. Schrock may publish in the future.

Co-authorship network of co-authors of Alexa B. Schrock

This figure shows the co-authorship network connecting the top 25 collaborators of Alexa B. Schrock. A scholar is included among the top collaborators of Alexa B. Schrock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexa B. Schrock. Alexa B. Schrock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Liquid biopsy detection of gene Copy Number (CN) losses including existing and emerging clinical targets 2024 ·Christian Rolfo,Jessica Lee,Lincoln W. Pasquina,Amaya Gascó,Alexa B. Schrock,Natasha B. Leighl	0
2	Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results 2024 ·Histopathology ·Douglas A. Mata,Jessica Lee,Vignesh Shanmugam,(unknown),Alexa B. Schrock,Erik A. Williams,Lauren L. Ritterhouse,Richard A. Hickman,Tyler Janovitz,Nimesh R. Patel,Benjamin Kroger,Jeffrey S. Ross,Kamran Mirza,Geoffrey R. Oxnard,Jo‐Anne Vergilio,Julia A. Elvin,Jamal Benhamida,Brennan Decker,Mina L. Xu	5
3	Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors. 2024 ·Journal of Clinical Oncology ·Dazhi Liu,(unknown),Alexa B. Schrock,Alexander Drilon,Justin Jee,Bob T. Li	1
4	Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice 2024 ·Clinical Cancer Research ·Debra L. Richardson,Júlia C.F. Quintanilha,Natalie Danziger,Gerald Li,Ethan Sokol,Alexa B. Schrock,Ericka M. Ebot,Neeru Bhardwaj,(unknown),(unknown),(unknown),(unknown),(unknown),Julia A. Elvin,Ryon P. Graf,Kathleen N. Moore	5
5	Abstract PO2-16-05: ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice 2024 ·Cancer Research ·Manali Bhave,Júlia C.F. Quintanilha,Ryon P. Graf,(unknown),(unknown),Gerald Li,Alexa B. Schrock,Geoffrey R. Oxnard,Mia Levy,Kevin Kalinsky	0
6	Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness 2023 ·JCO Precision Oncology ·Júlia C.F. Quintanilha,(unknown),Ryon P. Graf,Gerald Li,Rachel B. Keller,Douglas I. Lin,Jeffrey S. Ross,Richard S.P. Huang,Alexa B. Schrock,Geoffrey R. Oxnard,Sakti Chakrabarti,Amit Mahipal	31
7	Genomic landscape of 891 RET fusions detected across diverse solid tumor types 2023 ·npj Precision Oncology ·Vamsi Parimi,Khaled Tolba,Natalie Danziger,(unknown),(unknown),Douglas I. Lin,Matthew Hiemenz,Alexa B. Schrock,Jeffrey S. Ross,Geoffrey R. Oxnard,Richard S.P. Huang	34
8	Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response 2023 ·JCO Precision Oncology ·Jay A. Moore,(unknown),Russell W. Madison,Justin Y. Newberg,(unknown),(unknown),Radwa Sharaf,Karthikeyan Murugesan,Bernard J. Fendler,Jason D. Hughes,Alexa B. Schrock,Priti S. Hegde,Geoffrey R. Oxnard,David Fabrizio,Garrett M. Frampton,Emmanuel S. Antonarakis,Ethan S. Sokol,Dexter X. Jin	13
9	Unique Spectrum of Activating BRAF Alterations in Prostate Cancer 2023 ·Clinical Cancer Research ·Alex Chehrazi‐Raffle,Hanna Tukachinsky,(unknown),Smruthy Sivakumar,Alexa B. Schrock,(unknown),Hedyeh Ebrahimi,Sumanta K. Pal,Tanya B. Dorff,Neeraj Agarwal,Brandon A. Mahal,Geoffrey R. Oxnard,Justin H. Hwang,Emmanuel S. Antonarakis	8
10	Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature 2023 ·JCO Precision Oncology ·Felipe Batalini,Russell W. Madison,Ethan S. Sokol,Dexter X. Jin,(unknown),Brennan Decker,Dean C. Pavlick,Garrett M. Frampton,Gerburg M. Wulf,Judy E. Garber,Geoffrey R. Oxnard,Alexa B. Schrock,Nadine Tung	8
11	Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 2022 ·JCO Precision Oncology ·Hatim Husain,Dean C. Pavlick,Bernard J. Fendler,Russell W. Madison,Brennan Decker,Ole Gjoerup,Christine A. Parachoniak,(unknown),Rachel Erlich,Alexa B. Schrock,Garrett M. Frampton,Meghna Das Thakur,Geoffrey R. Oxnard,Hanna Tukachinsky	58
12	Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer 2022 ·Cancer Research Communications ·Ryon P. Graf,Virginia Fisher,James Creeden,Alexa B. Schrock,Jeffrey S. Ross,Halla Nimeiri,Geoffrey R. Oxnard,Samuel J. Klempner	7
13	Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma 2022 ·Modern Pathology ·(unknown),Tyler Janovitz,(unknown),Douglas A. Mata,Meagan Montesion,Jessica Lee,Russell W. Madison,Alexa B. Schrock,Hanna Tukachinsky,Justin Allen,Rachel Erlich,Matthew Hiemenz,Richard S.P. Huang,Julia A. Elvin,Jo‐Anne Vergilio,Douglas I. Lin,Jeffrey S. Ross,Geoffrey R. Oxnard,Brennan Decker	2
14	Response to MEK Inhibitor Therapy inMAP2K1(MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape ofMAP2K1Mutations in Non–Small-Cell Lung Cancer 2022 ·JCO Precision Oncology ·Michael L. Cheng,Jessica Lee,Rachit Kumar,(unknown),(unknown),Alexa B. Schrock,(unknown),Tali Mazor,Ethan Cerami,Geoffrey R. Oxnard,David Liu,Himisha Beltran,Lynette M. Sholl,Mizuki Nishino,Pasi A. Jänne	4
15	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation 2019 ·Clinical Cancer Research ·Benjamin P. Brown,Yunkai Zhang,David Westover,Yingjun Yan,Huan Qiao,Vincent Huang,Zhenfang Du,Jarrod A. Smith,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Lyudmila Bazhenova,Alexa B. Schrock,Jens Meiler,Christine M. Lovly	76
16	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence 2019 ·The Oncologist ·Samuel J. Klempner,David Fabrizio,Shalmali Bane,Marcia Reinhart,Tim Peoples,Siraj M. Ali,Ethan S. Sokol,Garrett M. Frampton,Alexa B. Schrock,Rachel Anhorn,Prasanth Reddy	243
17	Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus 2018 ·Clinical Cancer Research ·Alexa B. Schrock,Dean C. Pavlick,Samuel J. Klempner,Jon Chung,(unknown),Allison W. Welsh,Lauren Young,B Leyland-Jones,Rodolfo Bordoni,Richard D. Carvajal,Joseph Chao,Razelle Kurzrock,Jason K. Sicklick,Jeffrey S. Ross,Philip J. Stephens,Craig Devoe,Fadi Braiteh,Siraj M. Ali,Vincent A. Miller	54
18	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma 2018 ·Cancer Discovery ·Steven B. Maron,Lindsay Alpert,Heewon Kwak,Samantha Lomnicki,Leah M. Chase,David Xu,Emily O’Day,Rebecca J. Nagy,Richard B. Lanman,Franco Cecchi,Todd Hembrough,Alexa B. Schrock,John Hart,Shu‐Yuan Xiao,Namrata Setia,Daniel V.T. Catenacci	79
19	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy 2017 ·Cancer ·Siraj M. Ali,Ming Yao,Jicheng Yao,(unknown),Yu‐Wei Cheng,Alexa B. Schrock,Gung‐Wei Chirn,Hui Chen,Shuo Mu,Laurie M. Gay,Julia A. Elvin,James Suh,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,Kai Wang	36
20	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients 2014 ·Clinical Cancer Research ·Andrew P. Garner,Joseph M. Gozgit,Rana Anjum,Sadanand Vodala,Alexa B. Schrock,Tianjun Zhou,César Serrano,Grant Eilers,Mei‐Jun Zhu,Julia Ketzer,Scott Wardwell,Yaoyu Ning,Youngchul Song,Anna Kohlmann,Frank Wang,Tim Clackson,Michael C. Heinrich,Jonathan A. Fletcher,Sebastian Bauer,Victor M. Rivera	123

About Alexa B. Schrock

Alexa B. Schrock is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 259 papers that have together received 6.0k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (116 papers), Lung Cancer Treatments and Mutations (98 papers) and Colorectal Cancer Treatments and Studies (38 papers). The work is most often cited by research in Oncology (3.7k citations), Cancer Research (1.8k citations) and Pulmonary and Respiratory Medicine (3.1k citations). Alexa B. Schrock has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Siraj M. Ali, Jeffrey S. Ross, Vincent A. Miller, Sai‐Hong Ignatius Ou, Samuel J. Klempner, Philip J. Stephens, Garrett M. Frampton, David Fabrizio, Russell W. Madison and James Suh. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact